Buy Bpc 157 10 mg + bacteriostatic water
€23.84
BPC-157, 10 mg, with bacteriostatic water, is a synthetic GEPPPGKPADDAGLV pentadecapeptide format for analytical and in vitro laboratory research. Pharma Research .eu provides documented European supply subject to lot-specific purity and identity verification.
Buy BPC-157, 10 mg + Bacteriostatic Water, for Advanced Laboratory Research in Europe
BPC-157 is a synthetic 15-residue pentadecapeptide used as a laboratory reagent in peptide analytics, biochemical method development and controlled in vitro research. The commonly specified free-peptide sequence is H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH, with formula C₆₂H₉₈N₁₆O₂₂ and average molecular mass approximately 1,419.5 Da. Pharma Research .eu presents this 10 mg format with bacteriostatic water for qualified European laboratory teams.pubchem.ncbi.nlm.nih+2
Uncompromising Purity and Analytical Characterisation
BPC-157 should be defined as the linear pentadecapeptide:
H-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH
The free N-terminus and free C-terminal carboxylic acid should be stated explicitly. BPC-157 acetate is a different product form, with reported formula C₆₄H₁₀₂N₁₆O₂₄ and molecular mass approximately 1,479.6 g/mol. A supplier must therefore identify whether the 10 mg quantity refers to free BPC-157, acetate salt or another formulation.pubchem.ncbi.nlm.nih+1
For laboratory procurement, the suitable target is ≥99.0% purity by RP-HPLC, subject to confirmation by the actual lot-specific certificate of analysis. Some commercial research specifications report ≥99% HPLC purity, but the batch chromatogram and identity data should control acceptance.peptidesresearch+1
A complete CoA should include:
-
RP-HPLC purity percentage, method and chromatogram.
-
LC-MS, ESI-MS or high-resolution MS identity confirmation.
-
Full sequence and terminal-group designation.
-
Free-peptide, acetate or other salt-form information.
-
Molecular formula and molecular-mass assignment.
-
Visual appearance of the lyophilised material.
-
Residual-solvent results from synthesis and purification.
-
Water or residual-moisture content, where measured.
-
Heavy-metal or elemental-impurity results where included in the quality programme.
-
Lot number, manufacture date, retest date and storage requirements.
BPC-157 free peptide is commonly reported as C₆₂H₉₈N₁₆O₂₂, with average molecular mass approximately 1,419.5–1,419.56 g/mol. CAS Registry Number 137525-51-0 and PubChem CID 9941957 are widely associated with this form.pubchem.ncbi.nlm.nih+2
The product is normally supplied as a white to off-white lyophilised powder. Visual inspection can identify gross discolouration, vial damage or visible contamination, but cannot establish purity or identity. Analytical release should combine appearance assessment with RP-HPLC and mass-spectral confirmation.
High purity is essential because the proline- and glycine-rich sequence may generate deletion sequences, truncation products and closely related synthesis impurities. Additional species, residual water and counter-ions can affect peak integration, ionisation, solubility and concentration calculations. Lower-grade or non-characterised material may be unsuitable for quantitative LC-MS, stability-indicating methods or reproducible comparative research.
Bacteriostatic water is a separate reagent and should have its own label, expiry date, preservative information and documentation. Its excipients may affect chromatography, ionisation, adsorption, pH and cellular assay performance.
Principal Laboratory Applications and Research Methodologies
BPC-157 is suitable for controlled laboratory research involving pentadecapeptide chemistry, analytical characterisation and in vitro biochemical model development. All applications should be conducted by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.
RP-HPLC and LC-MS method development. BPC-157 can serve as a defined long-peptide analyte for retention-time assignment, intact-mass confirmation, impurity profiling and recovery studies. Its charged, polar sequence may require optimisation of mobile-phase pH, ionic strength, column chemistry and sample concentration.
Peptide identity and degradation profiling. Laboratories may monitor truncated sequences, oxidation products, hydrolysis-related species and other stress products using combined HPLC and mass spectrometry. A validated method should distinguish chemical degradation from adsorption, incomplete dissolution, matrix effects or instrument carryover.
In vitro biochemical and cellular models. A verified lot may be incorporated into controlled cell-free or cellular systems examining peptide-associated signalling or barrier-model responses. Experimental plans should include vehicle controls, blank matrices, concentration confirmation and independent assessment of peptide integrity during incubation.
Reference and system-suitability applications. A documented batch may support instrument checks, calibration development, retention-time comparison and sample-preparation validation. Unless formally certified under a recognised reference-material standard, it should be described as a research reference material or analytical reagent rather than a certified reference material.
If the entire 10 mg free-peptide quantity were dissolved in 3 mL, the nominal concentration would be approximately 3.33 mg/mL, or 2.35 mM, before correction for purity, salt form, water content and final volume. This is a formulation calculation only; the actual working concentration must be based on the lot-specific CoA and validated laboratory method.
The bacteriostatic-water component should not automatically be assumed suitable for every analytical or cellular workflow. Preservatives may require solvent blanks, matrix-effect studies and cell-compatibility testing. Laboratories should validate the selected diluent before using it in a quantitative workflow.
Compound Stability, Optimal Storage, and Safe Handling Protocols
BPC-157 should remain sealed in its lyophilised state until required for a validated laboratory procedure. Research handling references commonly recommend storing the dry peptide at approximately −20°C, protected from light and moisture. Prepared solutions require separate stability verification; commercial guidance about a fixed post-reconstitution period should not be treated as universal without product-specific supporting data.lyopep+2
Recommended controls include:
-
Store unopened lyophilised BPC-157 at approximately −20°C unless the CoA specifies otherwise.
-
Consider −80°C for extended archival storage where supported by the stability programme.
-
Keep the vial tightly closed, dry and protected from direct light.
-
Allow a sealed vial to reach room temperature before opening to minimise condensation.
-
Use low-binding tubes where adsorption could affect recovery.
-
Prepare aliquots if repeated vial access is expected.
-
Store short-term aqueous solutions at 2–8°C only where validated.
-
Use frozen aliquots for longer-term solution storage when supported by stability data.
-
Avoid repeated freeze–thaw cycles.
-
Record solvent, concentration, preparation date, operator and storage history.
Lyophilised BPC-157 is generally more stable than an aqueous solution, but prepared solutions may experience adsorption, concentration loss, pH-dependent changes or physical instability. A clear solution should not be assumed to retain full chemical integrity without HPLC or LC-MS confirmation.
Reconstitution should be carried out using a validated laboratory procedure. Add bacteriostatic water gradually, allow the powder to hydrate and mix gently. Avoid vigorous agitation unless its compatibility has been demonstrated. Confirm concentration and chromatographic integrity after preparation where quantitative results are required.
Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.
Technical Specifications and Molecular Attributes
| Attribute | Specification |
|---|---|
| Product | BPC-157, 10 mg, supplied with bacteriostatic water |
| Common designation | BPC-157; synthetic pentadecapeptide |
| Sequence | H-GEPPPGKPADDAGLV-OH |
| Residue count | 15 amino acids |
| IUPAC name | Full systematic peptide name should be confirmed on the CoA; sequence notation is preferred for procurement |
| CAS Registry Number | 137525-51-0 for commonly reported free BPC-157 |
| Molecular formula, free peptide | C₆₂H₉₈N₁₆O₂₂ |
| Average molecular mass, free peptide | Approximately 1,419.5–1,419.56 g/mol |
| Physical state and colour | Lyophilised white to off-white powder |
| Solubility profile | Aqueous reconstitution may be feasible; solvent and buffer compatibility require assay-specific validation |
| Typical purity | Proposed target ≥99.0% by RP-HPLC; verify the actual lot-specific result |
| Identity testing | LC-MS, ESI-MS or high-resolution MS |
| Companion reagent | Bacteriostatic water; volume and formulation should be confirmed on the packaging |
| Long-term storage | Typically −20°C, sealed and protected from light and moisture |
If the supplied material is BPC-157 acetate, the table must instead report its acetate-specific formula, molecular mass and CAS record. Free BPC-157 and BPC-157 acetate should not be combined under one technical specification.pubchem.ncbi.nlm.nih+2
Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents
Pharma Research .eu can position BPC-157 as a documented European laboratory reagent for analytical chemists, biochemists and laboratory managers requiring a defined pentadecapeptide. The product file should include a batch-specific CoA, SDS, sequence designation, purity result, identity data, terminal-group and salt-form information, and storage instructions for both the peptide and bacteriostatic water.
Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims concerning discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.
A quality-focused supplier should be able to discuss:
-
Free BPC-157 versus BPC-157 acetate.
-
RP-HPLC purity and LC-MS identity testing.
-
Residual solvents, moisture and elemental-impurity reporting.
-
Packaging configuration and container-closure integrity.
-
Compatibility of bacteriostatic water with analytical workflows.
-
Storage, transport and documentation requirements.
Pharma Research .eu should therefore be described as a potential European source for research-grade BPC-157, with vendor-specific certification and logistics claims verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.


Reviews
There are no reviews yet.